CD274 and hepatocellular carcinoma: The development of anti-PD-1, anti-programmed cell death-ligand 1 (PD-L1), and anti-CTLA-4 monoclonal antibodies has advanced the treatment for advanced cancer, resulting in numerous attempts to apply ICIs for the treatment of multiple advanced solid malignancies, including HCC.